{"id":4304,"date":"2022-06-18T09:00:12","date_gmt":"2022-06-18T09:00:12","guid":{"rendered":"https:\/\/healthdrum.com\/blog\/?p=4304"},"modified":"2022-06-15T19:24:22","modified_gmt":"2022-06-15T19:24:22","slug":"5-challenges-to-conventional-wisdom-in-prostate-cancer","status":"publish","type":"post","link":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/","title":{"rendered":"5 Challenges to Conventional Wisdom in Prostate Cancer"},"content":{"rendered":"

Patients with <\/span>prostate cancer<\/span><\/a> have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?<\/span><\/p>\n

Fifteen years ago, meta-researcher John Ioannidis, Ph.D., published <\/span>a seminal essay<\/span><\/a> \u2014 since viewed more than 3.2 million times \u2014 arguing that “most published research findings are false.” Ioannidis’s concerns are especially pertinent for clinicians who assume that their testing and treatment philosophies are inherently valid on the basis of studies designed to support these unfounded biases.<\/span><\/p>\n

Here are five evidence-based challenges to conventional dogma in prostate cancer treatment.<\/span><\/p>\n

<\/b>1. The rapid growth of prostate cancer treatment is not driving increased survival.<\/strong><\/p>\n

The North American market for prostate cancer treatments is poised to <\/span>reach USD $30.6 billion by 2025<\/span><\/a>. Yet, the annual US death rate is about 30,000 and slowly decreases as each decade passes. Surprisingly, this improvement in mortality is probably not based on early detection and treatment but rather on the effect of a gradual increase in life expectancy due to better treatment of infections and comorbidities.<\/span><\/p>\n

<\/b>2. Gleason grade 3 (as in Gleason 3+3=6) is not prostate cancer.<\/strong><\/p>\n

Laurence Klotz, MD, and others have determined that the grade 3 in the Gleason 3+3 = 6 score <\/span>lacks the hallmarks of cancer<\/span><\/a> on the basis of its clinical outcome and molecular biology. This would mean that the Gleason grade 6 should not be diagnosed as a cancer and should not be treated or included in prostate cancer statistics.
\n<\/span><\/p>\n

So, which prostate cancers are potentially lethal and responsible for the 30,000 annual deaths in the United States? Essentially, those diagnosed as Gleason grades 4+3, 4+4, and anything with 5s. On the other hand, those with 3+4s and particularly those with low amounts of pattern 4 disease \u2014 the critical amount is yet to be established\u00a0 \u2014 seem to have a natural history similar to that of the bogus Gleason grade 6 disease described above.
\n<\/span><\/p>\n

More important, because of the complexity and subjectivity of the Gleason grading system, interpretation errors and incorrect diagnoses based on Gleason scores are frequent. In fact, Swedish <\/span>pathologists disagreed about Gleason grades<\/span><\/a> a staggering 50% of the time. A figure easily understood since the Gleason score assessment requires at least ten estimations of growth patterns seen (primary and secondary grades, 5 each). Pattern 4 disease has an additional 4 arrangements <\/span>(ill-formed, fused, glomeruloid, and cribriform).<\/span> <\/a>Along with the percentage estimation of pattern 4 disease, there are clearly many opportunities for incorrect diagnoses.\u00a0<\/span><\/p>\n

Furthermore, prostate cancers not only exhibit different degrees of aggressiveness but also are affected by the phenomenon of field effects<\/a>, which may occur through genetic or epigenetic changes. This is common in the prostate. It also explains why cancer may be detected in more than one area of the prostate or develop in another part and be of a different grade when found during surveillance at a later date.<\/span><\/p>\n

<\/b>3. PSA-based screening does not save lives.<\/strong><\/p>\n

Prostate-specific antigen (PSA)-based screening, which may also include the unreliable prostate examination, fails to save significant numbers of lives. Data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial on prostate cancer mortality <\/span>demonstrated<\/span><\/a> that “PSA-based screening results in a small or no reduction in prostate cancer-specific mortality.” Yet, despite failing to save significant numbers of lives, some 30 million PSA tests are ordered in the United States each year, conferring unnecessary risks and well-documented overtreatment.<\/span><\/p>\n

The fact that PSA-based screening fails to save significant numbers of lives has been confirmed not only by urologists but also by others. Richard Ablin, who discovered PSA in 1970, and journalist Ronald Piana have demonstrated<\/a> that PSA testing is associated with a false-positive rate of about 78%, uses an arbitrary normal range of 0-4 ng\/mL, and is unable to distinguish between low- and high-risk prostate cancers because high-grade cancers often make little or no PSA. Even alternative biomarkers, including PSA derivatives, prostate cancer antigen 3, and genomic and urine tests, are not foolproof.<\/span><\/p>\n

The transrectal, ultrasound-guided, 12-core prostate needle biopsy component of PSA-based screening randomly samples only about 0.1% of the prostate gland when comparing the total volume of the 12 core samples taken by an 18-gauge needle with the size of an average prostate gland. The grossly unscientific 0.1% hit-or-miss biopsy means that there is zero knowledge about the remaining 99.9% of prostate tissue. This test is uncomfortable (despite local anesthetic) and carries a significant risk for <\/span>sepsis<\/span><\/a>, rectal bleeding, erection issues, and <\/span>depression<\/span><\/a>. Yet, shockingly, over 1 million core-needle biopsies are ordered in the United States each year \u2014 with costly complications.<\/span><\/p>\n

<\/b>4. Prostate cancer surgery for localized prostate cancer does not improve survival.<\/strong><\/p>\n

The era of prostate cancer treatment was ushered in with a surgical approach. In 1905, H.H. Young published his modified technique, “<\/span>The Early Diagnosis and Radical Cure of Carcinoma of the Prostate<\/span><\/a> .<\/span><\/a>” Despite the enthusiastic title, Young’s paper offered no evidence for early diagnosis of prostate cancer and zero evidence for a cure. Furthermore, Young’s conclusion that “The four cases in which the radical operation was done demonstrated its simplicity, effectiveness and the remarkably satisfactory functional results furnished” stands in very sharp contrast to his published results noting the deaths of his first two patients and prolonged hospital stays and significant urinary complications for the second two patients.<\/span><\/p>\n

The Prostate Cancer Intervention Versus Observation Trial (PIVOT) study cast further doubt on the usefulness of surgical treatment compared with active surveillance. Published in <\/span>The New England Journal of Medicine<\/span><\/i>, the <\/span>report<\/span><\/a> concluded, “Among men with localized prostate cancer detected during the early era of PSA testing, radical <\/span>prostatectomy<\/span><\/a> did not substantially reduce all-cancer or prostate cancer mortality, as compared with observation, through at least 12 years of follow up. Absolute differences were less than 3 percentage points.”<\/span><\/p>\n

Another <\/span>study done by urologists<\/span><\/a> ,<\/span><\/a> which followed patients for 29 years, implied that radical prostatectomy led to a “mean of 2.9 years of life gained.” However, the study included men with Gleason 6 disease and treated other participants with <\/span>testosterone<\/span><\/a> suppression, which itself can produce life extension.<\/span><\/p>\n

Adding to the confusion, surgical studies typically included patients with a mix of Gleason grades, scores, and tumor volumes. Additionally, prostate cancer has been commonly staged on the basis of CT scans and bone scans \u2014 both highly undependable because these technologies are not sensitive enough to detect small-volume cancer spread. This particular concern has been supported by <\/span>bone marrow aspiration studies<\/span><\/a> and the use of sophisticated staining techniques, suggesting the presence of micrometastasis in the bone marrow of men with negative staging studies.<\/span><\/p>\n

<\/b>5. Robotic prostatectomy has never been properly evaluated for safety and efficacy.<\/strong><\/p>\n

Despite a low-level clinical study in Mexico recording no benefit for the robotic device in gallbladder and fundoplication surgery, the US Food and Drug Administration (FDA) approved the wildly expensive surgical tool in 1999 on the basis that the robotic device “demonstrated potential for future enhancements to surgery.”
\n<\/span><\/p>\n

As a consequence, urologists were <\/span>quick to leverage the FDA’s 510(k) process<\/span><\/a> to obtain FDA approval in 2001 for use of the device in robotic prostatectomy. Remarkably, this <\/span>approval was achieved<\/span><\/a> without any supporting studies for safety or effectiveness. <\/span>Because robotic prostatectomy bypassed testing for safety and effectiveness, it’s not surprising that the list of complications associated with this surgery is alarmingly long<\/a>. Sexual and bladder problems are common. Because countless men became depressed with their results following prostate cancer surgery, both preoperative and postoperative penile and bladder “rehabilitation” counseling programs were established so that men were better prepared for the surgical after-effects. A prosthetic industry took root to make implantable urinary control and penile erection devices to “cure” these tragic complications. The failure of these gadgets has resulted in even more “corrective” surgery, higher costs, and greater suffering for patients struggling to maintain relationships with their loved ones.<\/span><\/p>\n

<\/b>To What End?<\/strong><\/p>\n

The 5-year survival rate for prostate cancer is estimated to be about 100%; the 10-year survival is estimated to be about 98%; and the 15-year survival is estimated to be about 96%, regardless of the type of treatment. Despite these survival rates, the prostate cancer market continues to grow. This is even more remarkable given that <\/span>10-year survival for early-stage disease is similar whether a patient was treated or not<\/span><\/a>. <\/span>Yet, the quest for early detection continues unabated with the current technology du jour, the <\/span>MRI-fusion study<\/span><\/a>. Sadly, history has made it abundantly clear that the early-detection-to-treatment mantra for prostate cancer is not only costly, inaccurate, and risky, but it simply fails to save a significant number of men. As a community, urology’s claim about delivering evidence-based, standard-of-care medicine is in urgent need of serious review and revision.<\/span><\/p>\n

Dedication to Anthony Horan, MD.<\/b><\/span><\/em>
\nThis article is dedicated to Anthony Horan MD, a urologist and author (The Big Scare) who fearlessly challenged the culture and the business of prostate cancer. He was always on the right side of what should never have been a controversy.<\/span><\/p>\n

Written by Bert Vorstman and published in Medscape February 23, 2021
\n<\/span><\/p>\n

Read more.<\/strong><\/p>\n

Ablin, R., and Piana R., \u201cThe Great Prostate Hoax\u201d.<\/span><\/p>\n

Horan, A., \u201cThe Big Scare\u201d.<\/span><\/p>\n

Horan, A., \u201cHow to Avoid The Overdiagnosis and Overtreatment of Prostate Cancer\u201d.<\/span><\/p>\n

Horan, A., \u201cThe Rise and Fall of the Prostate Cancer Scam\u201d.<\/span><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based? Fifteen years ago, meta-researcher John Ioannidis, Ph.D., published a seminal essay \u2014 since viewed more than […]<\/p>\n","protected":false},"author":4,"featured_media":4317,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[24],"tags":[46,45],"yoast_head":"\n5 Challenges to Conventional Wisdom in Prostate Cancer | HEALTHdrum<\/title>\n<meta name=\"description\" content=\"Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"5 Challenges to Conventional Wisdom in Prostate Cancer | HEALTHdrum\" \/>\n<meta property=\"og:description\" content=\"Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?\" \/>\n<meta property=\"og:url\" content=\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"HEALTHdrum\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/HEALTHdrum-103735818167546\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-18T09:00:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-15T19:24:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/healthdrum.com\/blog\/wp-content\/uploads\/2022\/05\/books-g5c6f936f1_1920-1-e1655316302185.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Bert Vorstman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@healthdrumapp\" \/>\n<meta name=\"twitter:site\" content=\"@healthdrumapp\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bert Vorstman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\"},\"author\":{\"name\":\"Bert Vorstman\",\"@id\":\"https:\/\/healthdrum.com\/blog\/#\/schema\/person\/953d5fca0a0cb8ee1915ae9f4ed3741a\"},\"headline\":\"5 Challenges to Conventional Wisdom in Prostate Cancer\",\"datePublished\":\"2022-06-18T09:00:12+00:00\",\"dateModified\":\"2022-06-15T19:24:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\"},\"wordCount\":1508,\"publisher\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/#organization\"},\"keywords\":[\"Cancer\",\"Prostate Cancer\"],\"articleSection\":[\"Prostate cancer\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\",\"url\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\",\"name\":\"5 Challenges to Conventional Wisdom in Prostate Cancer | HEALTHdrum\",\"isPartOf\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/#website\"},\"datePublished\":\"2022-06-18T09:00:12+00:00\",\"dateModified\":\"2022-06-15T19:24:22+00:00\",\"description\":\"Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?\",\"breadcrumb\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/healthdrum.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"5 Challenges to Conventional Wisdom in Prostate Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/healthdrum.com\/blog\/#website\",\"url\":\"https:\/\/healthdrum.com\/blog\/\",\"name\":\"HEALTHdrum\",\"description\":\"Blog | Cost-transparent Routine Medical Care | HEALTHdrum\",\"publisher\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/healthdrum.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/healthdrum.com\/blog\/#organization\",\"name\":\"HEALTHdrum\",\"url\":\"https:\/\/healthdrum.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/healthdrum.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/healthdrum.com\/blog\/wp-content\/uploads\/2021\/09\/HEALTHdrumLogo.png\",\"contentUrl\":\"https:\/\/healthdrum.com\/blog\/wp-content\/uploads\/2021\/09\/HEALTHdrumLogo.png\",\"width\":172,\"height\":76,\"caption\":\"HEALTHdrum\"},\"image\":{\"@id\":\"https:\/\/healthdrum.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/HEALTHdrum-103735818167546\",\"https:\/\/twitter.com\/healthdrumapp\",\"https:\/\/www.instagram.com\/healthdrum_app\/\",\"https:\/\/www.linkedin.com\/company\/healthdrum\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/healthdrum.com\/blog\/#\/schema\/person\/953d5fca0a0cb8ee1915ae9f4ed3741a\",\"name\":\"Bert Vorstman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/healthdrum.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3af75bb2e908bd808de6943957e36c33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3af75bb2e908bd808de6943957e36c33?s=96&d=mm&r=g\",\"caption\":\"Bert Vorstman\"},\"description\":\"Dr. Vorstman did his chief residency at Jackson Memorial hospital in Miami, Florida. Subsequently, he completed fellowship training in Pediatric and Adult Reconstructive Urology at the Eastern Virginia Medical School in Norfolk, Virginia. During his time there he also undertook NIH sponsored, pioneering research on \u201cUrinary Bladder Reinnervation\u201d earning him the honor of a Masters of Surgery Diploma through the University of Otago, New Zealand. Dr Vorstman returned to Miami to become a board-certified faculty member in the department of urology, Jackson Memorial Hospital, University of Miami. Eventually, he left academic practice, moved north to Coral Springs and established Florida Urological Associates pa (www.urologyweb.com) in 1987. Dr. Vorstman is passionate about consumer-directed healthcare and helping men diagnosed with prostate cancer navigate the minefield of prostate cancer misinformation. After retiring and leaving colleagues to continue the urology practice, he became founder and CEO of a healthcare platform that connects buyers and sellers of routine, cash pay healthcare services - www.HEALTHdrum.com\/ Through this platform he also enables colleagues to reclaim their profession from health industry exploitation. Partial bibliography https:\/\/ascopost.com\/issues\/june-10-2016\/prostate-cancer-opinions-vary-on-gleason-scores-and-surgery\/ https:\/\/ascopost.com\/issues\/november-25-2020\/a-urologic-surgeon-assesses-the-current-state-of-prostate-cancer\/ https:\/\/www.medscape.com\/viewarticle\/945928 https:\/\/urologyweb.com\/robotic-deception-prostate-cancer-hoax-p-5\/ https:\/\/bvorstman.medium.com\/prostate-cancer-treatment-deception-and-lies-30e23f17b749 https:\/\/healthdrum.com\/blog\/the-gleason-6-prostate-cancer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"5 Challenges to Conventional Wisdom in Prostate Cancer | HEALTHdrum","description":"Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/","og_locale":"en_US","og_type":"article","og_title":"5 Challenges to Conventional Wisdom in Prostate Cancer | HEALTHdrum","og_description":"Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?","og_url":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/","og_site_name":"HEALTHdrum","article_publisher":"https:\/\/www.facebook.com\/HEALTHdrum-103735818167546","article_published_time":"2022-06-18T09:00:12+00:00","article_modified_time":"2022-06-15T19:24:22+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/healthdrum.com\/blog\/wp-content\/uploads\/2022\/05\/books-g5c6f936f1_1920-1-e1655316302185.jpg","type":"image\/jpeg"}],"author":"Bert Vorstman","twitter_card":"summary_large_image","twitter_creator":"@healthdrumapp","twitter_site":"@healthdrumapp","twitter_misc":{"Written by":"Bert Vorstman","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/#article","isPartOf":{"@id":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/"},"author":{"name":"Bert Vorstman","@id":"https:\/\/healthdrum.com\/blog\/#\/schema\/person\/953d5fca0a0cb8ee1915ae9f4ed3741a"},"headline":"5 Challenges to Conventional Wisdom in Prostate Cancer","datePublished":"2022-06-18T09:00:12+00:00","dateModified":"2022-06-15T19:24:22+00:00","mainEntityOfPage":{"@id":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/"},"wordCount":1508,"publisher":{"@id":"https:\/\/healthdrum.com\/blog\/#organization"},"keywords":["Cancer","Prostate Cancer"],"articleSection":["Prostate cancer"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/","url":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/","name":"5 Challenges to Conventional Wisdom in Prostate Cancer | HEALTHdrum","isPartOf":{"@id":"https:\/\/healthdrum.com\/blog\/#website"},"datePublished":"2022-06-18T09:00:12+00:00","dateModified":"2022-06-15T19:24:22+00:00","description":"Patients with prostate cancer have a right to expect that their screening, diagnosis, and treatment are supported by evidence-based science. But how well does the urology community measure up when it comes to claims that standard-of-care practices are evidence-based?","breadcrumb":{"@id":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/healthdrum.com\/blog\/5-challenges-to-conventional-wisdom-in-prostate-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/healthdrum.com\/blog\/"},{"@type":"ListItem","position":2,"name":"5 Challenges to Conventional Wisdom in Prostate Cancer"}]},{"@type":"WebSite","@id":"https:\/\/healthdrum.com\/blog\/#website","url":"https:\/\/healthdrum.com\/blog\/","name":"HEALTHdrum","description":"Blog | Cost-transparent Routine Medical Care | HEALTHdrum","publisher":{"@id":"https:\/\/healthdrum.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/healthdrum.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/healthdrum.com\/blog\/#organization","name":"HEALTHdrum","url":"https:\/\/healthdrum.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/healthdrum.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/healthdrum.com\/blog\/wp-content\/uploads\/2021\/09\/HEALTHdrumLogo.png","contentUrl":"https:\/\/healthdrum.com\/blog\/wp-content\/uploads\/2021\/09\/HEALTHdrumLogo.png","width":172,"height":76,"caption":"HEALTHdrum"},"image":{"@id":"https:\/\/healthdrum.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/HEALTHdrum-103735818167546","https:\/\/twitter.com\/healthdrumapp","https:\/\/www.instagram.com\/healthdrum_app\/","https:\/\/www.linkedin.com\/company\/healthdrum\/"]},{"@type":"Person","@id":"https:\/\/healthdrum.com\/blog\/#\/schema\/person\/953d5fca0a0cb8ee1915ae9f4ed3741a","name":"Bert Vorstman","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/healthdrum.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3af75bb2e908bd808de6943957e36c33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3af75bb2e908bd808de6943957e36c33?s=96&d=mm&r=g","caption":"Bert Vorstman"},"description":"Dr. Vorstman did his chief residency at Jackson Memorial hospital in Miami, Florida. Subsequently, he completed fellowship training in Pediatric and Adult Reconstructive Urology at the Eastern Virginia Medical School in Norfolk, Virginia. During his time there he also undertook NIH sponsored, pioneering research on \u201cUrinary Bladder Reinnervation\u201d earning him the honor of a Masters of Surgery Diploma through the University of Otago, New Zealand. Dr Vorstman returned to Miami to become a board-certified faculty member in the department of urology, Jackson Memorial Hospital, University of Miami. Eventually, he left academic practice, moved north to Coral Springs and established Florida Urological Associates pa (www.urologyweb.com) in 1987. Dr. Vorstman is passionate about consumer-directed healthcare and helping men diagnosed with prostate cancer navigate the minefield of prostate cancer misinformation. After retiring and leaving colleagues to continue the urology practice, he became founder and CEO of a healthcare platform that connects buyers and sellers of routine, cash pay healthcare services - www.HEALTHdrum.com\/ Through this platform he also enables colleagues to reclaim their profession from health industry exploitation. Partial bibliography https:\/\/ascopost.com\/issues\/june-10-2016\/prostate-cancer-opinions-vary-on-gleason-scores-and-surgery\/ https:\/\/ascopost.com\/issues\/november-25-2020\/a-urologic-surgeon-assesses-the-current-state-of-prostate-cancer\/ https:\/\/www.medscape.com\/viewarticle\/945928 https:\/\/urologyweb.com\/robotic-deception-prostate-cancer-hoax-p-5\/ https:\/\/bvorstman.medium.com\/prostate-cancer-treatment-deception-and-lies-30e23f17b749 https:\/\/healthdrum.com\/blog\/the-gleason-6-prostate-cancer\/"}]}},"_links":{"self":[{"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/posts\/4304"}],"collection":[{"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/comments?post=4304"}],"version-history":[{"count":15,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/posts\/4304\/revisions"}],"predecessor-version":[{"id":4324,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/posts\/4304\/revisions\/4324"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/media\/4317"}],"wp:attachment":[{"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/media?parent=4304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/categories?post=4304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthdrum.com\/blog\/wp-json\/wp\/v2\/tags?post=4304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}